+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Dopamine Antagonist"

D Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

D Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 90 Pages
  • Global
From
Antiemetics and Antinauseants Global Market Report 2024 - Product Thumbnail Image

Antiemetics and Antinauseants Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
From
Global Antiemetic Drug Market 2023-2027 - Product Thumbnail Image

Global Antiemetic Drug Market 2023-2027

  • Report
  • July 2023
  • 179 Pages
  • Global
From
Antiemetics: Technologies and Global Markets - Product Thumbnail Image

Antiemetics: Technologies and Global Markets

  • Report
  • July 2018
  • 115 Pages
  • Global
From
From
From
From
From
From
From
From
From
From
From
Loading Indicator

The Dopamine Antagonist market within the context of Gastrointestinal Drugs is a subset of the pharmaceutical industry that focuses on the development and production of drugs that target the dopamine receptors in the gastrointestinal tract. These drugs are used to treat a variety of gastrointestinal disorders, including nausea, vomiting, and irritable bowel syndrome. Dopamine antagonists are also used to treat certain types of depression, anxiety, and schizophrenia. The dopamine antagonist market is highly competitive, with many companies vying for market share. Some of the major players in the market include GlaxoSmithKline, Pfizer, Merck, Novartis, and AstraZeneca. Other companies in the market include Sanofi, Takeda, and Daiichi Sankyo. Show Less Read more